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Background: Cell-derived microparticles are secreted in response to cell damage or dysfunction. Endothelial and
platelet dysfunction are thought to contribute to the development of multiple sclerosis (MS). Our aim here is, first,
to compare the presence of microparticles of endothelial and platelet origin in plasma from patients with different
clinical forms of MS and with clinically isolated syndrome. Second, to investigate the effect of microparticles on
endothelial barrier function.
Results: Platelet-poor plasma from 95 patients (12 with clinically isolated syndrome, 51 relapsing-remitting, 23
secondary progressive, 9 primary progressive) and 49 healthy controls were analyzed for the presence of platelet-
derived and endothelium-derived microparticles by flow cytometry. The plasma concentration of platelet-derived
and endothelium-derived microparticles increased in all clinical forms of MS and in clinically isolated syndrome
versus controls. The response of endothelial barriers to purified microparticles was measured by electric cell-substrate
impedance sensing. Microparticles from relapsing-remitting MS patients induced, at equivalent concentrations, a
stronger disruption of endothelial barriers than those from healthy donors or from patients with clinically isolated
syndrome. MS microparticles acted synergistically with the inflammatory mediator thrombin to
disrupt the endothelial barrier function.
Conclusions: Plasma microparticles should be considered not only as markers of early stages of MS, but also as
pathological factors with the potential to increase endothelial permeability and leukocyte infiltration.
Keywords: Multiple sclerosis, Clinically isolated syndrome, Microparticles, Endothelial barrier function, ThrombinBackground
Multiple sclerosis (MS) is an inflammatory neurodegenera-
tive disease of the central nervous system (CNS) that
predominantly affects young adults. MS is highly heteroge-
neous and is considered by some authors to be a conglom-
erate of neurological syndromes, in which inflammatory
damage and demyelination overlap with chronic neurode-
generation. This complexity means that current pharmaco-* Correspondence: jmillan@cbm.csic.es; evacm@ficyt.es
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article, unless otherwise stated.logical treatments are directed towards modifying the
course of the disease, although there is no effective cure for
this pathology [1]. Therefore, a better understanding of MS
pathogenesis may help to establish new therapeutic strat-
egies. In addition, improvement of early diagnostic tools
could help speed up the initiation of MS treatments.
The etiology of MS remains unknown but it is most
likely a combination of genetic and environmental factors
deregulating the immune response [2]. Vasculature plays
a central role in the disease [3-5]. Alteration of endothe-
lial barriers to small molecules and blood cells contribute
to the leukocyte infiltration that causes inflammation and
demyelination [6-9]. Endothelial permeability in the brain
is altered in different clinical forms of MS even duringCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Characteristics of controls and patients enrolled
in the study
Mean age (95% CI) Number (%) of females
Control (N = 49) 42.70 (23.11-62.95) 26 (53.10)
Patients (N = 95) 44.35 (11.80-73.88) 62 (66.67)
CIS: 12 36.41 (21.69-49.64) 10 (83.33)
RRMS: 51 39.95 (11.80-68.51) 35 (68.63)
SPMS: 23 53.51 (38.38-73.88) 14 (60.87)
PPMS: 9 52.68 (44.06-62.48) 3 (33.33)
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chronic activation of platelets is also associated with MS,
although their role or the role of the coagulation cascade
in this pathology still needs to be clarified [10]. A recent
proteomic analysis of active MS lesions confirmed the
importance of the coagulation cascade, in general, and of
thrombin-mediated signaling, in particular, in the inflam-
matory progression of this disease [11].
Clinically, MS is classified into relapsing-remitting
(RRMS), secondary progressive (SPMS) and primary
progressive (PPMS) subtypes. In 85% of patients who de-
velop definitive MS, onset involves an acute or subacute
neurological episode affecting the optic nerves, brainstem
or the spinal cord, known as clinically isolated syndrome
(CIS). Studies of the natural history of CIS patients are
heterogeneous in terms of the clinical presentation and
the duration of the follow up, but it is commonly
accepted that CIS patients are at high risk of developing
MS [12].
Microparticles (MPs) are small vesicles released by a
variety of cell types in response to inflammatory media-
tors [13,14]. These vesicles are able to bind and signal to
different cell types through the interaction of proteins
exposed in their surface with their cell counter-receptors
[13]. MPs have been proposed as markers of a variety of
pathological processes such as endothelial dysfunction
[15,16], systemic lupus erythematosus [17], rheumatoid
arthritis [17], stroke [18] and thrombosis [19], but their
potential role in the progression of these diseases is not
fully characterized. An increase in circulating MPs of
endothelial origin has been reported in the relapsing
phase of patients diagnosed with the RRMS form, which
suggests a correlation between MPs and neurological epi-
sodes [20]. Platelet-derived MPs have also been detected
in RRMS patients [21,22], but no comparative analysis of
MP levels in MS subtypes has been performed to date.
In the present study we present a comprehensive
analysis of circulating platelet- and endothelium-derived
MPs in the plasma of the different clinical forms of MS.
Compared with normal control subjects, we found a
significant and comparable increase in all subtypes,
including patients with typical CIS and already recovered,
or patients in the remission phase of the disease. Interest-
ingly, we found experimental evidence to suggest that
plasma MPs induce human endothelial barrier dysfunc-
tion and thus may play an active role in MS progression.
RRMS MPs had a stronger effect than CIS or control
MPs on transendothelial electric resistance (TEER), when
analyzed at the same concentration. TEER is inversely
proportional to endothelial monolayer permeability, indi-
cating that MP composition and effect on endothelial
barrier differ between MS patients and healthy donors.
We also report that MS MPs can potentiate the effect on
long-term barrier dysfunction of thrombin. Our resultsindicate that MP generation in plasma is an early and
permanent consequence of inflammatory demyelinating
events.
Results
We investigated MPs in platelet-poor plasma (PPP) from
49 healthy volunteers and 95 patients and the possible
role of these MPs in endothelial barrier function. The
characteristics of controls and patients are summarized
in Table 1.
Identification of MPs of platelet and endothelial origin in
human plasma
The PPPs from healthy donors and patients were analyzed
by flow cytometry to detect circulating vesicles or MPs of
less than 3 μm diameter (Figure 1A-C, left panels,
Figure 1D-F, top panels). We found MPs positive for
Annexin V, CD42b and CD31 (AnxV + CD42b + CD31+),
which suggests a platelet origin, and MPs positive for
Annexin V and CD31, but negative for the CD42b marker
(AnxV+/CD42b-/CD31+), which suggest an endothelial
origin (Figure 1A-B, central and right panels) [20,23].
Prior cytometer adjustments using isotype specific con-
trols indicated that the signal from these antibodies was
specific (Figure 1C, right panels, see Methods). Thus,
these two types of MPs were defined as platelet-derived
MPs (PMPs) and endothelial-derived MPs (EMPs). MPs
positive for the endothelial marker E-Selectin/CD62E +
were also found, which confirmed the endothelial origin
of an MP subset (Figure 1D-F). Prior cytometer adjust-
ments using isotype specific controls indicated that the
signal from anti E-Selectin/CD62E + antibody was specific
(Figure 1E,F, bottom panels, see Methods). Hence, EMPs
were identified by detecting the markers CD31 and CD42
(EMPs-CD31) or CD62E (EMPs-CD62E).
Plasma levels of PMPs and EMPs are elevated in patients
with CIS and all the clinical forms of MS
Plasma EMPs may reflect age-related endothelial
dysfunction [24]. In the healthy donors included in our
study, ranging from 24 to 62 years of age, no statistically
significant differences in MP number could be attributed
to gender or age (Figure 2A-F). This suggests that any
Figure 1 Detection of PMPs and EMPs in plasma. (A-C) Flow cytometry scattergraphs for the quantitation of PMPs and EMPs-CD31. MPs
smaller than 3 μm were identified by cytometry in the presence of 3 μm diameter beads (left graphs, squared area). These MPs were positive for
Annexin V (central graphs, squared areas). Additional incubation with anti-CD31 and CD42 antibodies (A, B, right graphs) yielded two populations:
AnxV+ MPs positive for CD31 and CD42 (Q2), which suggests a platelet origin for this MP subpopulation (PMP), and AnxV+ MPs, positive for CD31
and negative for CD42 (Q4), which suggests an endothelial origin (EMP). Prior incubation with an antibody isotype control (iso) yielded no positive
staining (C). (A) Plasma from healthy control, (B, C) plasma from multiple sclerosis patient (RR) (D-F) Flow cytometry scattergraphs showing the
identification of EMPs-CD62. A subset of MPs smaller than 3 μm beads (top graphs, squared area) was positive for an anti-CD62E antibody (CD62E)
(D, E, bottom graphs, squared areas) and negative for an antibody isotype control (iso) (F, bottom graph, squared area). (D) Plasma from a healthy
control (E, F) plasma from multiple sclerosis patient (RR).
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Figure 2 Gender and age have no effect on PMP and EMP counts in healthy controls. (A-C) Comparison of PMPs (A), EMPs-CD31 (B) and
EMPs-CD62E (C) counts between female and male healthy controls. MPs were identified and quantified by cytometry as in Figure 1. No significant
differences were observed (Student’s t-test). (D-F) No significant changes in PMPs (D), EMPs-CD31 (E) and EMPs-CD62E (F) levels were detected
in relation to age in healthy donors.
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attributed to these parameters. Next, we performed a
comparative analysis of circulating MP levels between
these control individuals and patients with CIS and all
clinical forms of MS. First, the analysis of the pool of all
MS patient samples revealed that the mean ± SD of the
counts/μl plasma were significantly higher than in
healthy controls for the three types of MPs analyzed:
27,203 ± 16,767 for PMPs vs. 15,646 ± 11,901 for controls
(p < 0.001) (Figure 1A,B; Figure 3A) 6,527 ± 4,554
EMPs-CD31 vs. 2,202 ± 2,783 for controls (p < 0.001)
(Figure 1A,B; Figure 3B), and 746 ± 642 for EMPs-
CD62E vs. 418 ± 289 for controls (p < 0.05) (Figure 1D,
E; Figure 3C). An elevated MP content was also detected
when each clinical form of MS was individually analyzed,
including the progressive forms, SPMS and PPMS,which are considered to have a less important inflamma-
tory component (Figure 4). The MP counts (mean ± SD)
for each form of MS is summarized in Table 2. PMPs
were higher than controls in CIS and all the MS forms,
but the increase was not statistically significant for CIS
patients (Figure 4A, Table 2). In addition, remarkable
and statistically significantly higher levels of EMPs-
CD31 were observed in samples from CIS and all MS
forms compared to control donors (Figure 4B, Table 2).
Finally, compared to control subjects, EMPs-CD62 were
augmented in CIS and all the MS forms, although this
increase was statistically significant only for CIS patients:
646 ± 195 vs. 418 ± 289 (p < 0.05) (Figure 4C). In sum-
mary and regarding the absolute values of MP counts,
our results show that patients with CIS and all the clin-
ical forms of MS have comparable levels of circulating
Figure 3 Circulating MPs are more abundant in MS patients.
Comparison of PMPs (A), EMPs-CD31 (B) and EMPs-CD62E (C)
counts in healthy controls (Ct) and MS patients. MPs were identified
and quantified by cytometry as in Figure 1. (***p < 0.001, *p < 0.05
vs. healthy controls).
Figure 4 MPs in the different clinical forms of MS. Comparison
of PMP (A), EMPs-CD31 (B) and EMPs-CD62E (C) counts in healthy
controls (Ct) and patients with CIS or MS. (*p < 0.05, **p < 0.01,
***p < 0.001 vs. healthy controls). CIS, clinically isolated syndrome.
RRMS, relapsing, remitting MS. SPMS, secondary progressive MS.
PPMS, primary progressive MS. Differences between pairs were
assessed by Student’s t-test. MPs concentrations were not able to
discriminate between the different clinical forms of MS (ANOVA).
Numerical data and results of statistical analysis are shown in Table 2.
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Table 2 Circulating MP counts in healthy controls and the different clinical forms of MS
PMPs mean (SD)
counts/μl
EMPs-CD31 mean (SD)
counts/μl
EMPs-CD62 mean (SD)
counts/μl
PMPs
p vs. Ct
EMPs-CD31
p vs. Ct
EMPs-CD62
p vs. Ct
Control 15,646 (11,901) 2,202 (2,784) 418 (289)
CIS 30,936 (22,550) 7,964 (6,888) 646 (195) n.s. <0.05 <0.05
RRMS 28,929 (18,247) 7,136 (6,088) 511 (231) <0.001 <0.001 n.s.
SPMS 34,188 (29,511) 7,512 (5,962) 629 (644) <0.01 <0.001 n.s.
PPMMS 26,422 (9,865) 6,460 (3,610) 699 (621) <0.05 <0.001 n.s.
(n.s.: not statistically significant). p values compared to Control group, Student’s t-test.
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individuals (Table 2).
MPs induce endothelial barrier dysfunction
Endothelial barrier dysfunction is a hallmark of MS. To
gain insight into the role of circulating MPs in MS we
compared the effect on endothelial barrier function of
MPs isolated from patients and healthy controls. We used
an electric cell-substrate impedance sensing (ECIS)
system that measures in real time the resistance of endo-
thelial monolayers to a weak electric current that cause
no effects on cells. This is called transendothelial electric
resistance (TEER) and is inversely proportional to the
permeability of the monolayer. To address the relevance
of MP-mediated TEER changes in each endothelial cell
type, cells were incubated in parallel with the inflamma-
tory cytokine tumor necrosis factor (TNF) as a positive
control of in vitro barrier disruption (Figure 5A) [25,26].
First, monolayers of human umbilical vein endothelial
cells (HUVECs) were incubated with growing concentra-
tions of MPs from healthy donors, CIS patients and
RRMS (RR-MPs) patients, the latter taken as paradigm of
patients in which the disease has already progressed
(Figure 5B and C). Control, CIS and RR-MPs had no
significant effects on constitutive TEER at concentrations
of 250 and 500 MP/μl. In contrast, MPs from RRMS
patients notably disrupted the endothelial barrier after 4 h
of incubation at 1,000 MP/μl (Figure 5B-D; Additional file
1: Figure S1A). These MPs decreased normalized TEER
by 77.14 ± 21.94%, (p = 0.004) (Figure 5D). Such decrease
was expressed as the percentage of the difference between
the TEER values obtained from unstimulated HUVEC
monolayers (before incubation with MPs) and the TEER
values measured in absence of cells (see Methods). In
addition, this decrease was comparable or even stronger
than that caused by TNF exposure (Figure 5A and 5D,
discontinuous line). In contrast, barrier alterations that
control and CIS MPs induced on endothelial barrier func-
tion at 1,000 MP/ml were clearly below the effect of TNF
and were considered minor (Figure 5A-D). Consistent
with the loss of TEER upon exposure to MPs from RRMS
patients, the confocal analysis of endothelial cells
incubated with these MPs showed the appearance ofintercellular gaps, detected by staining of F-actin and the
junctional markers VE-cadherin and ZO-1 (Figure 5E,
mask, see Methods). In contrast, intercellular gaps were
absent or rare in cells incubated with control and CIS
MPs. These intercellular gaps were measured as the per-
centage of empty spaces found in different regions of the
cell monolayer and increased from 0.20 ± 0.23% in cells
exposed to control MPs to 1.38 ± 0.59% in cells exposed
to RR-MPs (p < 0.02) (Figure 5E). Together, these data
suggest that MPs from RRMS patients have composition
and signaling properties different to control and CIS MPs.
To confirm this, we tested the effect of RR-MPs in a cell
model of human endothelium from the blood–brain
barrier (BBB), the HCMEC/D3 cells [27]. We found no
effect of MPs on HCMEC/D3 monolayers at concentra-
tions of 400 (Figure 6A) and 1,000 MP/μl (not shown).
However, barrier disruption caused by RR-MPs at 2000
MP/μl was stronger than that produced by TNF or by
control MPs at the same concentration (Figure 6A,
Additional file 1: Figure S1B). In the presence of RR-MPs,
resistance decreased by 16.83 ± 12.19% (p < 0.04), whereas
in the presence of 2,000 MP/μl of control MPs, the resist-
ance decreased only by 9.00 + 11.7% (p = 0.39), which was
no statistically significant. 66% of RR-MPs had an effect
higher than TNF versus only 20% for control MPs
(Figure 6A). In contrast with the effect observed in
HUVECs, the incubation with RR-MPs did not induce big
intercellular gaps in HCMEC/D3 cells, but caused a
significant decrease of the immunofluorescence staining
of VE-cadherin and ZO-1 at cell-cell junctions (Figure 6B).
This was expressed as the junctional index, in which the
ratio between the staining intensity at cell borders and
the staining at the cell inner area was measured per cell
in confluent cell monolayers. This ratio was normalized
to 1 for HCMEC/D3 that had not been exposed to MPs
(see Methods). Junctional index significantly decreased
only in the presence of RR-MPs. It was reduced to 0.14 ±
0.06 (p < 0.03) for VE-cadherin staining and to 0.33 + 0.03
(p < 0.002) for ZO-1 staining. Thus, healthy donors not
only have significantly less MPs in plasma than MS-
patients. At equal concentrations, MPs from RRMS
patients provoke higher disruption of endothelial barrier
properties that those from healthy donors.
Figure 5 Effect of MPs on HUVEC barrier function. (A) TNF is a paradigmatic stimulus that induces significant and progressive reduction of
TEER (normalized TEER) (B, C) Normalized TEER of confluent HUVECs left untreated (Medium) or exposed to MPs at the indicated concentrations.
MPs from one healthy control (Control 3) and one RRMS patient (RR 3) were compared in a (B) and MPs from one CIS patient and from a RRMS
patient (RR 2) were compared in (C). (D) Percentage of TEER decrease induced after 14 hours of incubation with Control, CIS and RR-MPs at 250,
500 and 1000 MP/μl (see Methods). Average TEER decrease in response to TNF is marked by discontinuous lines. **p = 0.004. (E) HUVECs left
untreated (Medium) of previously treated for 14 h with MPs from a healthy control and a RRMS (RR) patient at 1000 MP/μl were stained for the
cell-cell junction markers VE-cadherin and ZO-1 and for filamentous actin (F-actin). Semi-automated image processing identified intercellular gaps
in the images (mask) that were quantified respect to the total area of the cell monolayer (right graph). *p = 0.01. Bar, 20 μm.
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progression of experimental MS has recently been
shown [11]. Thrombin is an inflammatory mediator that
induces acute barrier contraction and subsequent long-
term inflammatory activation of the endothelium [28],
so we hypothesized that MPs with no apparent effect onendothelial barriers on their own, may sensitize cells to
thrombin-mediated barrier disruption. Twenty-two hours
after the addition of MPs, the endothelial responses to
thrombin were analyzed in HUVECs and HCMEC/D3
monolayers in which TEER had not been previously
altered by the initial incubation with MPs. Whereas
Figure 6 Effect of MPs on hCMEC/D3 barrier function. (A) Percentage of TEER decrease after 14 hours of incubation with the indicated MPs
at 400 and 2000 MP/μl. Left graph, control donors. Right graph, RRMS patients (RR). Average TEER decrease in response to TNF is marked by
discontinuous lines. Bottom table shows the percentage of MPs inducing a response stronger than control TNF on the endothelial barrier.
*p = 0.04. (B) VE-cadherin, ZO-1 and F-actin staining in HCMEC/D3 cells exposed for 14 h to MPs from a donor and a RRMS patient. MPs did not
induced big gaps in HCMEC/D3, as in HUVECs, but, instead, RR-MPs dispersed the junctional staining of VE-cadherin (top right graph) and ZO-1
(bottom right graph) quantified as the ratio between the staining intensity at cell-cell borders and at the inner cell area (Junctional index).
**p < 0.03, ***p < 0.002. Bar, 20 μm.
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disrupted by thrombin (Figure 7), we unexpectedly found
that the HCMEC/D3 cell line barely contracted in re-
sponse to this inflammatory mediator (not shown). This
suggests that transformed HCMEC/D3 cells may lack
some protein machinery important for a full response to
thrombin. We thus studied the effect of MPs and throm-
bin only in HUVEC barriers. The acute phase of contrac-
tion upon thrombin stimulation and the subsequent
TEER recovery were not affected by the presence of MPsin these endothelial cells (Figure 7). However, between 3
and 8 h after thrombin stimulation, cells initially exposed
to RR-MPs at 500 MP/μl gradually reduced their barrier
integrity. In contrast, the TEER decrease between 3 and
8 h after thrombin activation was transient and minor in
cells previously exposed to control or CIS MPs (Figure 7).
Together these data suggest that MPs have an effect on
endothelial barrier function either on their own, at higher
concentrations, or when acting synergistically at lower
concentrations with a proinflammatory stimulus, namely
Figure 7 Synergistic effect of MS-MPs and thrombin on
endothelial barrier function. Top graph. Representative experiment
in which HUVECs were incubated with MPs at concentrations
between 250 and 1000 MP/μl for 22 h. Then, 1 U/ml of thrombin
was added to those monolayers showing no alteration of TEER in
response to MPs. After thrombin-induced acute contraction and
subsequent barrier recovery, HUVECs preincubated with RRMS MPs
(RR3) undergo long-term decrease in TEER. Bottom table.
Percentage of Control (3 samples), CIS (2 samples), and RR-MPs
(3 samples) in which 500 MP/μl had no apparent effect on barrier
function, but induced long-term TEER decrease after
thrombin stimulation.
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data suggest that chronic exposure to MPs may contribute
to a long-term increase in extravasation of molecules
and cells from the bloodstream in MS patients. Further
investigation into the protein composition of MPs
from different clinical subtypes may help the design of
therapies in which the endothelial permeability in-
crease associated with this inflammatory disease could
be prevented.Discussion
In this study we show that the different clinical forms of
MS, including the progressive forms, are associated with
platelet and endothelial dysfunction, as determined by
an increase in the number of circulating platelet- and
endothelial cell-derived MPs [21,29]. Moreover, we dem-
onstrate that these vesicles may play an active role in the
progression of the disease by increasing endothelial
monolayer permeability.Circulating microparticles as potential markers of CIS and
MS
Different soluble markers have been described for MS in
plasma or cerebrospinal fluid [30-32]. Among others,
platelet endothelial cell adhesion molecule (PECAM)-1
(CD31) and E-Selectin (CD62E) are present in microvesi-
cles derived from endothelial cells during apoptosis or
upon inflammatory stimulation [29] and their concentra-
tion in plasma may account for the status of the endothe-
lium [33]. In our study we observed a remarkable
increase in PMPs and both EMPs in all MS clinical forms.
The fact that elevated levels of EMPs in CIS patients were
also found indicates that these circulating vesicles are a
chronic and early feature in patients experiencing proin-
flammatory demyelinating pathologies. Our results extend
and are partly consistent with a previous report showing
an increase in EMPs, defined as CD51+ in both the
exacerbation and remission phases of RRMS patients.
Interestingly, these authors find no differences in CD31+/
CD42b- MPs in patients during the remission phase, al-
though they elegantly show that isolated endothelia from
patients in both the exacerbation and remission phases of
the disease release similar levels of both CD31+ and
CD51+ MPs to plasma, which are higher than those
released by the endothelium of healthy controls [20]. Col-
lectively and in line with our results, this work indicates
that in the remission phase of RRMS, high levels of EMPs
can be found. However, MPs from the exacerbation and
remission phases of the disease probably differ in com-
position. On the other hand, we have found that plasma
PMPs were significantly increased in each MS subtype,
consistent with the elevated circulating PMPs previously
found in RRMS. These data are also consistent with a
pivotal role for platelets in MS [21,34]. PMPs were also
elevated in CIS patients, but this increase was not statisti-
cally significant. This suggests that platelet dysfunction
may occurs later than the endothelial dysfunction and
when the disease is definitively progressing. Indeed, plate-
lets have been found in human MS lesions and in the
CNS of mice in the EAE model. Platelet depletion in the
EAE model ameliorated the disease, which was associated
with a reduction in recruitment of leukocytes to the CNS.
Similar results were observed after treatment with an
anti-CD42b antibody. It is interesting to note that CD42b
is present at the PMP surface and therefore the potential
role of these vesicles in the progression of the disease
needs to be considered.
Signals that impair BBB function in MS are initially
originated in the central nervous system. It is of note
that in the early stages of this pathology, the microglia
releases reactive oxygen species, TNF and IFN-γ, all of
which can induce MP release [35]. Therefore, the initial
inflammatory foci initiating the progression of the dis-
ease may cause the early secretion of EMP. In summary,
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in CIS and the remitting phase of RRMS, suggesting
enduring endothelial dysfunction from the very early
stages of demyelinating pathologies. These results make
PMPs and EMPs good candidates for clinical markers to
identify and discriminate between CIS and early MS.
Circulating microparticles as active players in MS
progression
The remarkable ability of MPs to induce cell signaling
and to promote endothelial dysfunction has already been
reported [36]. PMPs may activate leukocytes and induce
their transendothelial migration [37]. Moreover, MPs
promote a procoagulant status due to the presence of
phosphatidylserine in the outer part of the membrane
[38]. All this evidence suggests a potential role for MPs in
the progression of different pathologies, including MS.
The endothelial beds are highly exposed to circulating
MPs and therefore, more likely to respond to MP-
mediated signaling. The data presented here demonstrate
that MPs alone increase endothelial permeability. More-
over, this effect differs between definitive MS, stronger,
and CIS patient and control donors, which are more
attenuated when compared at the same concentration,
suggesting differences in the composition of these micro-
vesicles. Various mechanisms could mediate the effect of
MPs on endothelial barrier function. MPs expose surface
receptors with the potential to regulate endothelial per-
meability. The marker CD31, used for the identification
of EMPs, can establish homotypic interactions and modu-
late endothelial permeability [26]. EMPs also regulate the
production of reactive oxygen species (ROS) [39]. ROS
increase causes disruption of the endothelial barriers. On
the other hand, MPs from microvascular endothelial cells
and from atherosclerotic plaques contain matrix metallo-
proteinases involved in the cleavage and shedding of
surface proteins, including that of TNF [40,41]. Thus,
MPs may contribute to the release of cytokines that lo-
cally increase permeability. Indeed, MPs have been shown
to act as proinflammatory agents. MPs from monocytes
contain inflammatory cytokines with the potential to
modulate permeability and components of the inflamma-
some. These MPs activate the transcription factor NF-κB
and induce the expression of adhesion receptors in the
endothelium [42]. Finally, MPs also transport RNA and
micro (mi) RNA, which have the potential to modulate
protein expression in the target cell [43]. Some miRNAs,
such as miRNA155 negatively affects BBB function during
neuroinflammation [44]. Hence, the analysis of the differ-
ent composition of healthy and MS microparticles could
reveal novel targets for preventing endothelial barrier
disruption during the progression of the disease.
MS is considered to be a chronic inflammatory disease
in which several inflammatory mediators play a relevantlong-term function in its progression. Permanent expos-
ure to these mediators is probably the origin of the MP
increase but, importantly, it may also amplify the effect
of MPs on the endothelium. In the EAE model, it has
been reported that thrombin inhibition ameliorates the
neurological symptoms, indicating a deleterious effect of
this mediator in the exacerbation phase [11]. In MS,
various proteins involved in coagulation, including tissue
factor, which activates thrombin, become more abundant
in chronic active plaques [11]. Thrombin is therefore a
cytokine at the crossroads of inflammation and coagula-
tion with a remarkable ability to signal to and to alter the
barrier properties of endothelial cells, thereby possibly
contributing to the progress of MS. Our data indicate
that preincubation with RR-MPs has a long-term effect
on the endothelial barrier response to thrombin-
mediated challenge, which induces a secondary decrease
in TEER between 3 and 8 h post-stimulation. As men-
tioned above, MPs can deliver proinflammatory mole-
cules. This synergic effect on thrombin-mediated signaling
occurs within a time frame compatible with the modula-
tion of the expression of genes related to inflammation
and barrier function [28] rather than an effect on acute
actomyosin-mediated contraction [45]. Therefore, MS-
MPs may alter the vasculature on their own, or potentiate
the effects of proinflammatory mediators on endothelial
barrier dysfunction. This may have important and unex-
plored consequences for the progression of MS. Further
studies are necessary to determine which components of
MS-MPs are responsible for the observed effects.
Conclusions
Our findings demonstrate that platelet and endothelial
functions are altered in the different clinical forms of
MS, since patients show an increase in circulating MPs
of endothelial and platelet origin. In addition, endothelial
MPs are also significantly increased in CIS patients. In
vitro, MPs from MS patients disrupt endothelial barriers
and may thus cooperate in the progression of the disease.
Methods
Patients and controls
Eighty-three adult MS patients who met the criteria of
Poser [22] and MacDonald [46], 12 adult patients with a
typical CIS, suggestive of MS, and 49 healthy adult
volunteers gave their written informed consent and were
enrolled in the study, which was approved by the Ethics
Committee of the Hospital Universitario Central de
Asturias (Oviedo). MS exacerbation was defined as a
worsening of neurological impairment or the appearance
of a new symptom attributable to MS and lasting for at
least 24 hours. Patients were exacerbation-free and none
had any corticosteroids for at least one month before
entering the study.
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Venous blood was collected in citrate vacutainer tubes
with a 21G needle. Blood was centrifuged within 20 min
of extraction. PPP was obtained by centrifugation for
20 min at 1,550 g. Aliquots were immediately frozen and
preserved at −80°C until use.
Antibodies and chemicals
PE-conjugated anti-CD31 was from eBioscience (San
Diego, CA, USA). APC-conjugated anti-CD42b was pur-
chased from BD Bioscience (Erembodegem, Belgium).
FITC-conjugated anti-CD62E (E-Selectin) was obtained
from Santa Cruz Biotech (Santa Cruz, CA, USA). FITC-
conjugated Annexin V was from ImmunoStep (Salamanca,
Spain). Recombinant fibronectin, thrombin and other
chemicals were provided by Sigma-Aldrich (St Louis,
MO, USA).
Flow cytometry
A volume of 20 μl of PPP was incubated with 2 μl of the
indicated antibodies or their corresponding isotypic con-
trols at room temperature for 20 min with gentle shaking
(100 rpm). Following this, 900 μl of PBS containing a
fixed number of 3-μm latex beads were added. For the
AnxV +MP determination, 4 μl of FITC-conjugated
AnxV were added with the antibodies and the sample
was subsequently diluted in 900 μl of AnxV buffer con-
taining the latex beads. MPs present in the samples were
measured in a FACSAria cytometer with the FACSDiva
software (BD Bioscience, Erembodegem, Belgium). To
determine the fluorescence background, isotypic anti-
bodies for each fluorochrome were used. Compensation
adjustments were made based on fluorescence minus one
(FMO) controls, which consist of all the reagents but the
one of interest. The absolute number of MPs was esti-
mated through the formula: [MP/μl plasma] = (n° events
counted per test * n° beads per test)/(n° events in bead
region * test volume). 10,000 beads were routinely col-
lected. All solvents were 0.22-μm filtered.
Cell culture
HUVECs were purchased from Lonza (Barcelona, Spain)
and grown in fibronectin-coated plates in EBM-2
medium supplemented with 2% fetal bovine serum, glu-
tamine, penicillin/streptomycin and the endothelial cell
growth supplement EGM-2 [26]. Immortalized hCMEC/
D3 cells were obtained as previously described [27] and
grown in rat collagen-I-coated plates (Cultrex) in EBM-2
medium supplemented with 5% fetal bovine serum, peni-
cillin/streptomycin, hydrocortisone (Sigma), ascorbic acid
(Sigma), Chemically Defined Lipid Concentrate (Invitro-
gen), HEPES (PAA The Cell Culture Company) and hu-
man bFGF (Sigma).Isolation of MPs
PPP from patients and controls was centrifuged at 3,200
g for 30 min and subsequently at 13,000 g for 10 min to
remove cell debris. Supernatants were then centrifuged
at 18,000 g for 45 min and the pellet of MPs washed and
resuspended in EC culture medium. Final MP counts
were determined by flow cytometry.
Endothelial permeability assays
Cells were grown to confluency on fibronectin-coated
(HUVECs) or rat-collagen-I coated (hCMEC/D3) eight-well
array culture-ware (8WE10, Ibidi, München, Germany)
specific for transendothelial electric resistance (TEER)
measurements with the electric cell substrate impedance
sensing (ECIS) system 1600R (Applied Biophysics [26].
The experiments were performed in wells in which the
electric resistance of the EC monolayer, which is inversely
proportional to its permeability, had reached a steady-
state. EC monolayers were incubated with MPs isolated
from controls and patients and the effect on permeability
monitored by at least 14 h. The percentage of maximum
permeability increase induced by MPs was calculated tak-
ing into account that the average normalized resistance
(NR) for an ECIS electrode containing no cells or fully
contracted cells (maximum permeability) is 0.35, whereas
untreated, control confluent monolayers yielded an aver-
age NR value of approximately 1.10 for hCMEC/D3 and
0.95-1.00 for HUVECs 14 h after the beginning of the
experiment. Thus, the percentage of reduction in resist-
ance was calculated applying the formula [(NR unstimu-
lated cells-NR MPs)/0.75] X100, NR being the normalized
resistance value 14 h after the beginning of the ECIS read-
ing. A parallel incubation with 10 ng/ml human TNF (R &
D) was performed to measure the responsiveness of
hCMEC/D3 and HUVEC barriers to inflammatory chal-
lenges. 22 h after exposure to the indicated MPs, the ECIS
was paused, 1U/ml of human thrombin was added and its
effect recorded in the instrument for an additional period
of 10 h.
Immunofluorescence analysis
Endothelial cells were grown at confluency for 48 h in
Ibidi μ-slide 8 well dishes pre-coated with fibronectin
(HUVECs) or rat-collagen-I (hCMEC/D3). Cells were
incubated with MPs from control donors or patients at
the indicated concentrations for at least 14 h. In parallel,
ECIS assays were performed with the same MPs to de-
tect changes in endothelial barrier function. Then, cells
were fixed in 4% paraformaldehyde for 20 min, rinsed
and treated with 10 mM glycine for 5 min to quench the
aldehyde groups. The cells were then permeabilized with
0.2% Triton X-100, rinsed and incubated with 3% bovine
serum albumin in PBS for 15 min. Cells were incubated
for 30 min with the indicated antibodies at 37°C, rinsed
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escent secondary antibodies. Actin filaments were detected
with fluorescent phalloidin. Confocal laser scanning micros-
copy was carried out using a Zeiss LSM 510 microscope
equipped with a 63 × 1.3 NA oil immersion objective.
Intercellular gaps in confluent monolayers were quanti-
fied using Image J. Ten images containing around twenty
cells were quantified per condition and experiment in
three different experiments. The image contrast was
semi-automatically increased to saturation, so regions in
the confluent monolayer that yielded no signal in all the
fluorescence channels were taken as empty areas or inter-
cellular gaps, and selected by creating a threshold. The
percentage of empty areas respect to total image area was
calculated. To show the empty areas, the region obtained
with the threshold was blue-colored and flattened to the
original image.
When intercellular gaps were not big enough to be
detected, the junctional index was calculated. The junc-
tional index quantified the junctional/non-junctional
staining ratio for junctional proteins and was also calcu-
lated using Image J. Ten images containing around twenty
cells were quantified per condition and experiment. The
background was substracted using the BG Substraction
from ROI pluging from Image J. A region that selected
the total area of a single cell in the confluent monolayer
was created. This initial region was made 5 to 10 pixels
smaller using enlarge tool. The intensity of this smaller
region was quantified as non-junctional intensity of VE-
cadherin or ZO-1. The area between the initial region
and the smaller region was considered as junctional.
The junctional index was normalized taking as 1 the ratio
from cells not exposed to MPs.
Statistical analysis
Statistical analyses were performed using SPSS 15.0 for
Windows. One-way ANOVA (analysis of variance) was
used to analyze differences among three or more groups.
Pairs of groups were compared using Student’s t test
(parametric data) or the Mann Whitney U test (nonpara-
metric data). Bivariate correlations were estimated by
Spearman’s rank correlation (R). All tests for statistical
significance were two-tailed and values of p < 0.05 were
considered statistically significant.Additional file
Additional file 1: Figure S1. Absolute values of TEER detected in
endothelial cell monolayers exposed for 14 h to MPs from healthy
controls and patients. (A) TEER of HUVECs incubated with 1000 MP/μl
from healthy controls, CIS and RRMS (RR) patients (see Figure 5D). Red
line marks the average resistance detected in empty electrodes. (B) TEER
of HCMEC/D3 incubated with 2000 MP/μl from healthy controls, and
RRMS patients (see Figure 6B). Discontinuous line marks the average
resistance of TNF-stimulated cells.Abbreviations
MS: Multiple sclerosis; RRMS: Relapsing, remitting MS; SPMS: Secondary
progressive MS; PPMS: Primary progressive MS; CIS: Clinically isolated
syndrome; CNS: Central nervous system; BBB: Blood–brain barrier;
PPP: Platelet-poor plasma; MPs: Microparticles; PMPs: Platelet-derived MPs;
EMPs: Endothelial-derived microparticles; EC: Endothelial cell; HUVEC: Human
umbilical vein endothelial cell; TNF: Tumor necrosis factor;
TEER: Transendothelial electric resistance; ECIS: Electric cell-substrate
impedance sensing; AnxV: Annexin V; SD: Standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BMR performed the experiments of barrier function, immunofluorescence
and statistical analysis. PON analyzed MPs and performed statistical analysis.
ESP contributed to identify and isolate plasma MPs. MABG analyzed MPs and
performed statistical analysis. BBW provided the BBB cellular model and
valuable advice. IAR and POC provided the BBB cellular model. AT recruited
patients and analyzed data. CLR provided additional financial support and
critically reviewed of the manuscript. JM and ECM designed experiments,
supervised the research, wrote and edited the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by grants from the Ministerio de Ciencia e
Innovación (Spain) SAF2011–22624 (to J.M.) and PI080566 (to C.L-L.) and
from the CSIC (Spain) 200920I117 (to J.M.) and by Biogen-Idec (to J.M). P.O-N
was supported by Biogen-Idec. B.M-R was supported by a FPI fellowship from
the Ministerio de Ciencia e Innovación. E.S-P. was supported by a Severo
Ochoa Fellowship (FICYT, Consejería de Educación y Ciencia, Spain). E.C-M.
was supported by the Juan de la Cierva program (Ministerio de Ciencia e
Innovación, Spain). We acknowledge support of the publication fee by the
CSIC Open Access Publication Support Initiative through its Unit of
Information Resources for Research (URICI).
Author details
1Centro de Biología Molecular Severo Ochoa, CSIC-UAM, C/ Nicolás Cabrera 1,
Cantoblanco 28049, Madrid, Spain. 2Neurology Department, Hospital
Universitario Central de Asturias, C/ Aldea Cerdeño, s/n, 33011 Oviedo, Spain.
3Immunology Department, Hospital Universitario Central de Asturias, Oviedo,
Spain. 4Weill Medical College of Cornell University, New York, NY, USA.
5Department of Life Sciences, The Open University, Milton Keynes, UK. 6Division
of Hematology and Medical Oncology, Institut Cochin, Université Paris
Descartes, Paris, France.
Received: 11 February 2014 Accepted: 17 September 2014
Published: 22 September 2014
References
1. Compston A, Coles A: Multiple sclerosis. Lancet 2008, 372:1502–1517.
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple
sclerosis. N Engl J Med 2000, 343:938–952.
3. Kermode AG, Thompson AJ, Tofts P, MacManus DG, Kendall BE, Kingsley DP,
Moseley IF, Rudge P, McDonald WI: Breakdown of the blood–brain barrier
precedes symptoms and other MRI signs of new lesions in multiple
sclerosis. Pathogenetic and clinical implications. Brain 1990,
113(Pt 5):1477–1489.
4. Minagar A, Jy W, Jimenez JJ, Alexander JS: Multiple sclerosis as a vascular
disease. Neurol Res 2006, 28:230–235.
5. Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA,
McQuaid S: Blood–brain barrier disruption and enhanced vascular
permeability in the multiple sclerosis model EAE. J Neuroimmunol 2010,
229:180–191.
6. Brosnan CF, Raine CS: Mechanisms of immune injury in multiple sclerosis.
Brain Pathol 1996, 6:243–257.
7. Plumb J, McQuaid S, Mirakhur M, Kirk J: Abnormal endothelial tight
junctions in active lesions and normal-appearing white matter in
multiple sclerosis. Brain Pathol 2002, 12:154–169.
8. Kirk J, Plumb J, Mirakhur M, McQuaid S: Tight junctional abnormality in
multiple sclerosis white matter affects all calibres of vessel and is
Marcos-Ramiro et al. BMC Neuroscience 2014, 15:110 Page 13 of 13
http://www.biomedcentral.com/1471-2202/15/110associated with blood–brain barrier leakage and active demyelination.
J Pathol 2003, 201:319–327.
9. Leech S, Kirk J, Plumb J, McQuaid S: Persistent endothelial abnormalities
and blood–brain barrier leak in primary and secondary progressive
multiple sclerosis. Neuropathol Appl Neurobiol 2007, 33:86–98.
10. Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, Steven
Alexander J, Minagar A: Role of platelets in neuroinflammation: a
wide-angle perspective. J Neuroinflammation 2010, 7:10.
11. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, Fernald GH,
Gerlitz B, Robinson WH, Baranzini SE, Grinnell BW, Raine CS, Sobel RA, Han
DK, Steinman L: Proteomic analysis of active multiple sclerosis lesions
reveals therapeutic targets. Nature 2008, 451:1076–1081.
12. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M: Clinically
isolated syndromes suggestive of multiple sclerosis, part I: natural
history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005,
4:281–288.
13. Mause SF, Weber C: Microparticles: protagonists of a novel
communication network for intercellular information exchange. Circ Res
2010, 107:1047–1057.
14. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM,
Tedgui A: Endothelial microparticles in diseases. Cell Tissue Res 2009,
335:143–151.
15. Wang JM, Huang YJ, Wang Y, Xu MG, Wang LC, Wang SM, Tao J: Increased
circulating CD31+/CD42- microparticles are associated with impaired
systemic artery elasticity in healthy subjects. Am J Hypertens 2007,
20:957–964.
16. Loyer X, Vion AC, Tedgui A, Boulanger CM: Microvesicles as cell-cell
messengers in cardiovascular diseases. Circ Res 2014, 114:345–353.
17. Sellam J, Proulle V, Jungel A, Ittah M, Miceli Richard C, Gottenberg JE, Toti F,
Benessiano J, Gay S, Freyssinet JM, Mariette X: Increased levels of
circulating microparticles in primary Sjogren’s syndrome, systemic lupus
erythematosus and rheumatoid arthritis and relation with disease
activity. Arthritis Res Ther 2009, 11:R156.
18. Simak J, Gelderman MP, Yu H, Wright V, Baird AE: Circulating endothelial
microparticles in acute ischemic stroke: a link to severity, lesion volume
and outcome. J Thromb Haemost 2006, 4:1296–1302.
19. Lacroix R, Dubois C, Leroyer AS, Sabatier F, Dignat-George F: Revisited role
of microparticles in arterial and venous thrombosis. J Thromb Haemost
2013, 11(Suppl 1):24–35.
20. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, Horstman
LL, Ahn YS: Elevated plasma endothelial microparticles in multiple
sclerosis. Neurology 2001, 56:1319–1324.
21. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A:
Evidence of platelet activation in multiple sclerosis. J Neuroinflammation
2008, 5:27.
22. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC,
Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic
criteria for multiple sclerosis: guidelines for research protocols. Ann
Neurol 1983, 13:227–231.
23. Jy W, Horstman LL, Jimenez JJ, Ahn YS, Biro E, Nieuwland R, Sturk A,
Dignat-George F, Sabatier F, Camoin-Jau L, Sampol J, Hugel B, Zobairi F,
Freyssinet JM, Nomura S, Shet AS, Key NS, Hebbel RP: Measuring circulating
cell-derived microparticles. J Thromb Haemost 2004, 2:1842–1851.
24. Markiewicz M, Richard E, Marks N, Ludwicka-Bradley A: Impact of
endothelial microparticles on coagulation, inflammation, and
angiogenesis in age-related vascular diseases. J Aging Res 2013,
2013:734509.
25. Bradley JR: TNF-mediated inflammatory disease. J Pathol 2008,
214:149–160.
26. Fernandez-Martin L, Marcos-Ramiro B, Bigarella CL, Graupera M, Cain RJ,
Reglero-Real N, Jimenez A, Cernuda-Morollon E, Correas I, Cox S, Ridley AJ,
Millan J: Crosstalk between reticular adherens junctions and platelet
endothelial cell adhesion molecule-1 regulates endothelial barrier func-
tion. Arterioscler Thromb Vasc Biol 2012, 32:e90–e102.
27. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M,
Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F,
Greenwood J, Romero IA, Couraud PO: Blood–brain barrier-specific
properties of a human adult brain endothelial cell line. FASEB J 2005,
19:1872–1874.
28. Chen D, Dorling A: Critical roles for thrombin in acute and chronic
inflammation. J Thromb Haemost 2009, 7(Suppl 1):122–126.29. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS: Endothelial
cells release phenotypically and quantitatively distinct microparticles in
activation and apoptosis. Thromb Res 2003, 109:175–180.
30. Dore-Duffy P, Newman W, Balabanov R, Lisak RP, Mainolfi E, Rothlein R,
Peterson M: Circulating, soluble adhesion proteins in cerebrospinal fluid
and serum of patients with multiple sclerosis: correlation with clinical
activity. Ann Neurol 1995, 37:55–62.
31. Correale J, Bassani Molinas Mde L: Temporal variations of adhesion
molecules and matrix metalloproteinases in the course of MS.
J Neuroimmunol 2003, 140:198–209.
32. Losy J, Niezgoda A, Wender M: Increased serum levels of soluble PECAM-
1 in multiple sclerosis patients with brain gadolinium-enhancing lesions.
J Neuroimmunol 1999, 99:169–172.
33. Dignat-George F, Boulanger CM: The many faces of endothelial
microparticles. Arterioscler Thromb Vasc Biol 2011, 31:27–33.
34. Langer HF, Choi EY, Zhou H, Schleicher R, Chung KJ, Tang Z, Gobel K, Bdeir
K, Chatzigeorgiou A, Wong C, Bhatia S, Kruhlak MJ, Rose JW, Burns JB, Hill
KE, Qu H, Zhang Y, Lehrmann E, Becker KG, Wang Y, Simon DI, Nieswandt B,
Lambris JD, Li X, Meuth SG, Kubes P, Chavakis T: Platelets contribute to the
pathogenesis of experimental autoimmune encephalomyelitis. Circ Res
2012, 110:1202–1210.
35. Centonze D, Muzio L, Rossi S, Furlan R, Bernardi G, Martino G: The link
between inflammation, synaptic transmission and neurodegeneration in
multiple sclerosis. Cell Death Differ 2010, 17:1083–1091.
36. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, Mostefai HA, Draunet-Busson
C, Leftheriotis G, Heymes C, Martinez MC, Andriantsitohaina R: Endothelial
dysfunction caused by circulating microparticles from patients with
metabolic syndrome. Am J Pathol 2008, 173:1210–1219.
37. Mause SF, von Hundelshausen P, Zernecke A, Koenen RR, Weber C: Platelet
microparticles: a transcellular delivery system for RANTES promoting
monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol 2005,
25:1512–1518.
38. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F,
Freyssinet JM: Procoagulant microparticles: disrupting the vascular
homeostasis equation? Arterioscler Thromb Vasc Biol 2006, 26:2594–2604.
39. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS: Endothelium-derived
microparticles impair endothelial function in vitro. Am J Physiol Heart Circ
Physiol 2004, 286:H1910–H1915.
40. Lozito TP, Tuan RS: Endothelial cell microparticles act as centers of matrix
metalloproteinsase-2 (MMP-2) activation and vascular matrix remodeling.
J Cell Physiol 2012, 227:534–549.
41. Canault M, Leroyer AS, Peiretti F, Leseche G, Tedgui A, Bonardo B, Alessi MC,
Boulanger CM, Nalbone G: Microparticles of human atherosclerotic
plaques enhance the shedding of the tumor necrosis factor-alpha
converting enzyme/ADAM17 substrates, tumor necrosis factor and
tumor necrosis factor receptor-1. Am J Pathol 2007, 171:1713–1723.
42. Wang JG, Williams JC, Davis BK, Jacobson K, Doerschuk CM, Ting JP,
Mackman N: Monocytic microparticles activate endothelial cells in an
IL-1beta-dependent manner. Blood 2011, 118:2366–2374.
43. Burger D, Schock S, Thompson CS, Montezano AC, Hakim AM, Touyz RM:
Microparticles: biomarkers and beyond. Clin Sci (Lond) 2013, 124:423–441.
44. Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J,
Kay O, de Vries HE, Hirst MC, Sharrack B, Baker D, Male DK, Michael GJ,
Romero IA: MicroRNA-155 negatively affects blood–brain barrier function
during neuroinflammation. FASEB J 2014, 28:2551–2565.
45. van Nieuw Amerongen GP, Draijer R, Vermeer MA, van Hinsbergh VW:
Transient and prolonged increase in endothelial permeability induced
by histamine and thrombin: role of protein kinases, calcium, and RhoA.
Circ Res 1998, 83:1115–1123.
46. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin
FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M,
Thompson AJ, Weinshenker BG, Wolinsky JS: Diagnostic criteria for
multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol
2005, 58:840–846.
doi:10.1186/1471-2202-15-110
Cite this article as: Marcos-Ramiro et al.: Microparticles in multiple
sclerosis and clinically isolated syndrome: effect on endothelial barrier
function. BMC Neuroscience 2014 15:110.
